Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 8:44 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 3001–3024 of 4,076 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Self-study Clear all

Conditions: Depression, Mild Cognitive Impairment
Interventions: Not listed
Lead sponsor: Miro Health; Other
Eligibility: 60 Years and older
Enrollment: 960 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Sacramento, California • Miami, Florida

Conditions: Young Adult, Cancer, Physical Activity
Interventions: Step-Up Intervention; Behavioral
Lead sponsor: University of Wisconsin, Milwaukee; Other
Eligibility: 18 Years to 39 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Milwaukee, Wisconsin

Conditions: Epilepsy
Interventions: perampanel; Drug
Lead sponsor: Mid-Atlantic Epilepsy and Sleep Center, LLC; Other
Eligibility: 18 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cardiopulmonary Disease, Smoking Cessation, Inpatient
Interventions: Enhanced Usual Care (EUC), Nurse Practitioner Tobacco Treatment Team (NPT3); Other
Lead sponsor: Baystate Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 424 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Springfield, Massachusetts

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Batefenterol + Fluticasone Furoate, Placebo, Albuterol; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 10
States / cities: Phoenix, Arizona • Hollywood, Florida • Baltimore, Maryland + 7 more

Conditions: Lower Urinary Tract Symptoms
Interventions: Lactobacillus; Drug
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 6 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 2
States / cities: Washington D.C., District of Columbia

Conditions: Fertility Risk
Interventions: Subsidy for fertility consult, Invitation to purchase fertility consult; Other
Lead sponsor: Turtle Health, Inc.; Industry
Eligibility: 25 Years to 35 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Epidermolysis Bullosa
Interventions: Cellutome Epidermal Harvesting System; Device
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Not listed
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Physical Inactivity
Interventions: MAP to Health; Behavioral
Lead sponsor: HealthPartners Institute; Other
Eligibility: 40 Years to 64 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Bloomington, Minnesota

Conditions: A Healthcare Professional, a Patient or Caregiver in the Radiation Oncology Department at the University of Pennsylvania
Interventions: Art therapy; Behavioral
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years to 70 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Prostate Cancer (Diagnosis)
Interventions: The Stockholm3 test; Diagnostic Test
Lead sponsor: Karolinska Institutet; Other
Eligibility: 45 Years to 75 Years · Male only
Enrollment: 2,152 participants
Timeline: 2019 – 2023
U.S. locations: 13
States / cities: Los Angeles, California • Palo Alto, California • Chicago, Illinois + 4 more

Conditions: Refractory Chronic Cough, Unexplained Chronic Cough, Cough Hypersensitivity
Interventions: Cough Management, CoughMonitor Suite; Behavioral · Device
Lead sponsor: Hyfe Inc; Other
Eligibility: 21 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Wilmington, Delaware

Conditions: Opioid Use Disorder, Chronic Pain
Interventions: Patient-Oriented Dosing (POD), Pain Self-Management (PSM), Usual Care, Standard Buprenorphine Dosing Condition; Drug · Behavioral
Lead sponsor: Erin Winstanley; Other
Eligibility: 18 Years and older
Enrollment: 273 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 13
States / cities: Baltimore, Maryland • Dundalk, Maryland • Hagerstown, Maryland + 6 more

Conditions: Adolescent Idiopathic Scoliosis
Interventions: Brace, Observation; Device · Other
Lead sponsor: Stuart L. Weinstein, MD; Other
Eligibility: 10 Years to 15 Years
Enrollment: 383 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 22
States / cities: Madera, California • Sacramento, California • San Diego, California + 18 more

Conditions: Nicotine Use Disorder
Interventions: Realtime biofeedback using fMRI; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 65 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Breast Cancer
Interventions: Polysomnography (PSG), Rectal thermistor 400 Series, Bright blue-green light, Dim red light, Digital foot candle datalogging light meter, Patient-Reported Outcomes Measurement Information System (PROMIS)-Cancer-Fatigue, Patient-Reported Outcomes Measurement Information System (PROMIS)-Sleep Disturbance, Patient-Reported Outcomes Measurement Information System (PROMIS)-Depression, Patient-Reported Outcomes Measurement Information System (PROMIS)-Physical Function, Pittsburgh Sleep Quality Index (PSQI), Center for Epidemiological Studies - Depression, Montreal Cognitive Assessment (MoCA), European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire (EORTC QLQ-C30), Daily Log; Diagnostic Test · Other
Lead sponsor: Michigan State University; Other
Eligibility: 21 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: East Lansing, Michigan

Conditions: Breast Neoplasms, Musculoskeletal Pain
Interventions: Hypnosis, Attention Control; Behavioral
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older · Female only
Enrollment: 191 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Type 2 Diabetes Mellitus
Interventions: SAR425899, Placebo, Liraglutide, Metformin; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 296 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 23
States / cities: Sheffield, Alabama • Huntington Park, California • Los Angeles, California + 18 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Insulin Glargine (HOE901 - U300), Insulin Glargine (HOE901 - U100), Background therapy; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 65 Years and older
Enrollment: 1,014 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 64
States / cities: Saraland, Alabama • Fresno, California • Greenbrae, California + 57 more

Conditions: Hemophilia B
Interventions: Gene Transfer, scAAV2/8-LP1-hFIXco; Genetic · Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 18 Years and older · Male only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2026
U.S. locations: 3
States / cities: Stanford, California • Memphis, Tennessee • Temple, Texas

Conditions: Stress Disorders, Post-Traumatic, Shame, Guilt, Sexual Assault and Rape
Interventions: Cognitive Processing Therapy, Self-Compassion Therapy; Behavioral
Lead sponsor: Christal L Badour; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Chronic Pain, Opioid Use Disorder, Opioid Misuse and Addiction
Interventions: Usual Care, Pain Self-Management; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 17
States / cities: Baltimore, Maryland • Allison Park, Pennsylvania • Blawnox, Pennsylvania + 9 more

Conditions: Vestibular Disorder, Educational Problems, Attention Deficit Disorder
Interventions: VestibulOTherapy; Behavioral
Lead sponsor: VestibulOTherapy; Industry
Eligibility: 6 Years to 10 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: La Crosse, Wisconsin

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: UMEC/VI DPI, Placebo DPI, Albuterol/salbutamol MDI; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 10
States / cities: Jasper, Alabama • Saint Charles, Missouri • Charlotte, North Carolina + 7 more

Search by objective public record fields.

The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over

Step-Up Intervention for Self-Management of Fatigue in Young Adults Receiving Chemotherapy

Perampanel for Treatment of Adults With Refractory Focal Epilepsy : a Pilot Study.

Smoking Cessation Pharmacotherapy-Nurse Practitioner Led Tobacco Treatment Team Study

Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease

Impact of Probiotics on Urinary Symptoms in Spinal Cord Injury SCI and SB

Care Expansion Across Remote Environments - Sub-Study of the SELF-GYN1 Trial

Study of Cellutome System for Treatment of Individual Lesions in EB Pts

MAP to Health Pilot Study: A Physical Activity Intervention for Midlife Adults

A PHASE I, SINGLE-CENTER, MIXED METHODS STUDY ON THE HEALTH OUTCOMES OF VISUAL SELF EXPRESSION

Stockholm3 Validation Study in a Multi-Ethnic Cohort

Cough Management Wellness App for Refractory or Unexplained Chronic Cough

Pain Self-Management and Patient-Oriented Dosing for Pain and in Retention Opioid Treatment

Bracing in Adolescent Idiopathic Scoliosis Trial (BrAIST)

Real Time fMRI and Quitting Smoking

Effects of Bright Light on Co-occurring Cancer-related Symptoms in Breast Cancer Survivors

Hypnosis to Reduce Aromatase Inhibitor Pain and Improve Adherence

A Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus

Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications

Dose-Escalation Study Of A Self Complementary Adeno-Associated Viral Vector For Gene Transfer in Hemophilia B

Healthy Recovery After Trauma Study

Pain Self-Management and Treatment Engagement for Patients Taking Opioids

VestibulOTherapy: Vestibular Impact on Learning

A Study to Evaluate the Effect of the Combination of Umeclidinium (UMEC) and Vilanterol (VI) on Exercise Endurance Time (EET) in Participants With Chronic Obstructive Pulmonary Disease (COPD)